Trust Investment Advisors reduced its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 8.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,405 shares of the medical research company’s stock after selling 600 shares during the quarter. Trust Investment Advisors’ holdings in Edwards Lifesciences Corporation were worth $700,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Ardevora Asset Management LLP bought a new stake in shares of Edwards Lifesciences Corporation in the 3rd quarter worth approximately $33,755,000. Teacher Retirement System of Texas increased its position in shares of Edwards Lifesciences Corporation by 14.7% in the third quarter. Teacher Retirement System of Texas now owns 6,116 shares of the medical research company’s stock worth $669,000 after acquiring an additional 784 shares in the last quarter. First National Trust Co. increased its position in shares of Edwards Lifesciences Corporation by 13.4% in the third quarter. First National Trust Co. now owns 9,164 shares of the medical research company’s stock worth $1,002,000 after acquiring an additional 1,083 shares in the last quarter. Bridgecreek Investment Management LLC increased its position in shares of Edwards Lifesciences Corporation by 6.3% in the third quarter. Bridgecreek Investment Management LLC now owns 44,970 shares of the medical research company’s stock worth $4,916,000 after acquiring an additional 2,675 shares in the last quarter. Finally, Toronto Dominion Bank increased its position in shares of Edwards Lifesciences Corporation by 12.6% in the third quarter. Toronto Dominion Bank now owns 80,040 shares of the medical research company’s stock worth $8,747,000 after acquiring an additional 8,934 shares in the last quarter. Institutional investors and hedge funds own 82.17% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was first published by Daily Political and is the property of of Daily Political. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.dailypolitical.com/2017/11/14/trust-investment-advisors-reduces-position-in-edwards-lifesciences-corporation-ew.html.

Several research firms have recently weighed in on EW. Bank of America Corporation lifted their target price on shares of Edwards Lifesciences Corporation from $140.00 to $150.00 and gave the stock a “buy” rating in a research report on Thursday, July 27th. BidaskClub downgraded shares of Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 19th. SunTrust Banks, Inc. lifted their target price on shares of Edwards Lifesciences Corporation to $14.00 and gave the stock a “buy” rating in a research report on Monday, July 17th. Canaccord Genuity reissued a “buy” rating and issued a $155.00 target price (up from $150.00) on shares of Edwards Lifesciences Corporation in a research report on Sunday, July 30th. Finally, William Blair reissued an “outperform” rating on shares of Edwards Lifesciences Corporation in a research report on Monday, August 28th. Seven investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $125.17.

Shares of Edwards Lifesciences Corporation (EW) traded up $1.39 during trading on Tuesday, hitting $105.24. 1,104,700 shares of the stock were exchanged, compared to its average volume of 1,647,799. The company has a debt-to-equity ratio of 0.33, a current ratio of 3.49 and a quick ratio of 2.76. Edwards Lifesciences Corporation has a twelve month low of $81.12 and a twelve month high of $121.45. The firm has a market capitalization of $22,110.00, a PE ratio of 28.77, a price-to-earnings-growth ratio of 1.86 and a beta of 0.46.

Edwards Lifesciences Corporation (NYSE:EW) last issued its quarterly earnings data on Tuesday, October 24th. The medical research company reported $0.84 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.86 by ($0.02). Edwards Lifesciences Corporation had a return on equity of 27.22% and a net margin of 22.47%. The firm had revenue of $821.50 million during the quarter, compared to analyst estimates of $833.85 million. During the same quarter in the previous year, the firm posted $0.68 earnings per share. Edwards Lifesciences Corporation’s quarterly revenue was up 11.1% compared to the same quarter last year. equities research analysts anticipate that Edwards Lifesciences Corporation will post 3.75 EPS for the current year.

In related news, CEO Michael A. Mussallem sold 32,900 shares of the company’s stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $112.45, for a total transaction of $3,699,605.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Schack Wesley W. Von sold 1,000 shares of the company’s stock in a transaction on Thursday, November 9th. The shares were sold at an average price of $104.15, for a total transaction of $104,150.00. Following the transaction, the director now owns 2,622 shares of the company’s stock, valued at $273,081.30. The disclosure for this sale can be found here. Insiders sold 139,580 shares of company stock valued at $15,143,994 over the last 90 days. 2.13% of the stock is owned by corporate insiders.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.